SOMAÍ Pharmaceuticals Unipessoal LDA, European pharmaceutical cannabis product manufacturer, has received authorisation for its facility located in Lisbon, Portugal from the Portuguese Health Authority INFRAMED.
This authorisation permits the company to manufacture, import, and export medicinal cannabis products to numerous global markets and represents a significant step for the company towards revenue generation. The company also announces that it has successfully raised €5 million (USD $5.3 million) of new capital to fund its ambitious growth plans.
This INFRAMED authorisation awards the company a GMP Certificate Part I and Part II, enabling it to execute its plan to own distribution channels in Australia and Germany and to establish distribution partnerships in another eight countries whilst developing a comprehensive brand of medical cannabis products. SOMAÍ’s goal is to be a singular brand that services all doctors’ and patients’ needs through multiple delivery systems and novel formulations.
Our focus pivots from development to full commercialisation and growth by servicing all the current major markets and preparing smaller and new markets to open to medical cannabis
- Anton Nakhodkin, Board Member and MD
Michael Sassano, SOMAÍ’s Founder and CEO, stated: “We started construction in November 2021. We began manufacturing after an initial inspection 12 months later. Now, after receiving full GMP Part I and Part II, we have proven that it is possible to be in the market with pharmaceutical products in under two years. Furthermore, not only are products continually rolling out of stability from earlier this year, but we continue to create a full suite of next-generation products based on the future needs of patients.”
Anton Nakhodkin, Board Member and MD said: “Our focus pivots from development to full commercialisation and growth by servicing all the current major markets and preparing smaller and new markets to open to medical cannabis. Management hit and exceeded all targets and unlocked another €5 million (USD $5.4 million) of new investment to build out an international sales and distribution force.”
SOMAÍ remains extremely confident that the market for finished dosage form medical cannabis products has enormous potential. With the largest suite of products, SOMAÍ is invested in that future, and the company is already witnessing global demand and interest in its products from both legacy and new markets.